Takashita E, et al. Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018. Euro Surveill. 2019 Jan;24(3).
The novel cap-dependent endonuclease inhibitor baloxavir marboxil was approved for the treatment of influenza virus infection in Japan in February 2018. Two influenza A(H3N2) viruses carrying an I38T substitution in the polymerase acidic subunit (PA) were detected in baloxavir-treated children in December 2018. This mutation is known to confer reduced susceptibility to baloxavir, and the two mutant viruses exhibited 76- and 120-fold reduced susceptibility to baloxavir.
See Also:
Latest articles in those days:
- Analysis of a diffusive epidemic model with a zero-infection zone 8 minute(s) ago
- Quick detection of H5N1 avian influenza virus by surface enhanced Raman scattering(SERS) using aptamer capture 15 minute(s) ago
- The critical role of RAGE in severe influenza infection: A target for control of inflammatory response in the disease 35 minute(s) ago
- Human infection caused by avian influenza A (H10N5) virus 39 minute(s) ago
- Cross-species spill-over potential of the H9N2 bat influenza A virus 13 hours ago
[Go Top] [Close Window]